Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial

An experimental drug combination for preventing graft-versus-host disease was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of Hematology annual meeting.

http://www.eurekalert.org/pub_releases/2012-12/dci-egd121012.php